<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01081561</url>
  </required_header>
  <id_info>
    <org_study_id>#20090780</org_study_id>
    <nct_id>NCT01081561</nct_id>
  </id_info>
  <brief_title>Collagen Cross-Linking for Keratoconus/Ectasia With and Without Intacs</brief_title>
  <official_title>Randomized Study of Corneal Collagen Cross-Linking With the UV-X System for the Treatment of Keratectasia in Eyes With Intacs Compared to Eyes Without Intacs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yaron S. Rabinowitz M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cornea Genetic Eye Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the efficacy of collagen cross linking for progressive keratoconus
      and ectasia after lasik. It will try and determine which is a more effective treatment:
      collagen cross linking alone or collagen cross linking combined with Intacs, a treatment
      which has already been proven to be effective in decreasing corneal curvature in patients
      with keratoconus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study we will attempt to determine whether Collagen Cross Linking alone, one combined
      with insertion of INTACS is the most effective treatment for patients with progressive
      keratoconus in patients who have progressive disease.

      These treatments have been widely used outside of the United States for the treatment of
      progressive keratoconus. Corneal Collagen Cross linking was recently approved in the United
      States for the treatment of progressive keratoconus. We will attempt to study 600 patients
      total. 300 patients will be assigned to cross linking only while another 300 will be assigned
      to cross linking and INTACS. Once adequate number of study subjects have been recruited data
      will be analyzed to determine which treatment is more effective. The following parameters
      from Topography, OCT and Tomography will be studied(these are Max K(pentacam) Kvalue(Tomey
      Topography)I-Svalue(Tomey Topography Astigmatism(Tomey Topography) and Min OCT(corneal
      pachymetry) any one of these metrics that achieve a value of 1 or more will be included in
      the analysis since the cornea is so irregular that values less than one could be artifact
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 21, 2009</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness of UV-X cross linking to halt progression of keratoconus</measure>
    <time_frame>10 years</time_frame>
    <description>Any change of 1 or more of the following indices will be classified as progression. The following parameters will be studied Max K, Steep K, I-S value,Min OCT(pachymetry</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Keratoconus</condition>
  <condition>Ectasia</condition>
  <arm_group>
    <arm_group_label>Cross-linking</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Corneal collagen cross-linking with riboflavin and UVA light</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cross-linking plus INTACS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Corneal collagen cross-linking with riboflavin and UVA light plus INTACS</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riboflavin</intervention_name>
    <description>Removal of the epithelium, riboflavin drops every 2 minutes for 30 minutes follow by UV light radiation and addition riboflavin drops every 2 minutes for 30 minutes. Some subjects will be randomized to recieve INTACS prior to treatment with riboflavin.</description>
    <arm_group_label>Cross-linking</arm_group_label>
    <arm_group_label>Cross-linking plus INTACS</arm_group_label>
    <other_name>Peschke Meditrade</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  progressive keratoconus or ectasia

        Exclusion Criteria:

          -  cornea thinner than 400um

          -  K readings greater than 60D

          -  Central corneal scarring
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yaron S Rabinowitz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cornea Genetic Eye Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ezra Maguen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>american eye institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yuri Oleynikov, M.D. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cornea Genetic Eye Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Salz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laser Eye Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronald Gaster, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cornea Eye Institute, Beverly Hills</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cornea Eye Institute, 50 North La Cienaga Blvd, #340</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>March 4, 2010</study_first_submitted>
  <study_first_submitted_qc>March 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2010</study_first_posted>
  <last_update_submitted>October 1, 2018</last_update_submitted>
  <last_update_submitted_qc>October 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cornea Genetic Eye Institute</investigator_affiliation>
    <investigator_full_name>Yaron S. Rabinowitz M.D.</investigator_full_name>
    <investigator_title>Yaron S Rabinowitz M.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
    <mesh_term>Dilatation, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riboflavin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

